Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Digene

This article was originally published in The Gray Sheet

Executive Summary

Digene: Gains premarket approval application supplement approval to use its Hybrid Capture human papillomavirus (HPV) assay to test for HPV directly from Cytyc's PreservCyt sample vial -- which is currently used with the ThinPrep 2000 automated cervical sample preparation system. The approval allows a single cervical specimen preserved in PreservCyt solution to be microscopically evaluated via ThinPrep processing and then tested with the Hybrid Capture test if the screen is inconclusive. Digene entered a strategic alliance with Cytyc in October 1996 for joint marketing of Digene's Hybrid Capture HPV test and Cytyc's ThinPrep 2000 automated cervical sample preparation system ("The Gray Sheet" Oct. 14, I&W-7)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel